LRP6 (Ser1490): Regulating Myocardial Paracrine Signaling to Suppress Pressure Overload-Induced Cardiac Fibrosis

1. Concept

Low-density lipoprotein receptor-related protein 6 (LRP6) is a key co-receptor in both canonical and non-canonical Wnt signaling pathways, playing essential roles in embryonic development and adult tissue homeostasis. Phosphorylation at serine 1490 (Ser1490) is a critical activation event for LRP6, directly influencing its conformation, stability, and downstream signaling interactions. In the context of cardiovascular disease, pressure overload—caused by conditions like hypertension or valvular heart disease—triggers pathological cardiac remodeling, including cardiomyocyte hypertrophy and cardiac fibrosis (excessive extracellular matrix deposition). LRP6 (Ser1490) acts as an endogenous protective molecule, regulating myocardial paracrine signaling to suppress fibrosis and preserve cardiac function, making it a pivotal target for cardiovascular research and therapy.

2. Research Frontiers

Recent advances have uncovered the unique anti-fibrotic mechanism of LRP6 (Ser1490) in pressure overload-induced cardiac remodeling. Studies using cardiomyocyte-specific LRP6 overexpression mouse models (tamoxifen-inducible) and transverse aortic constriction (TAC) surgery demonstrate that enhanced LRP6 signaling improves cardiac systolic/diastolic function, inhibits pathological hypertrophy, and suppresses myocardial fibrosis. Mechanistically, LRP6 binds to lysosomal protease cathepsin D (CTSD) to promote the uptake and degradation of pro-fibrotic paracrine factors (Wnt5a, Wnt11) secreted by cardiomyocytes under pressure overload, reducing their extracellular concentration and blocking fibroblast activation.

Clinical correlation studies link LRP6 or CTSD loss-of-function mutations to higher Wnt5a/Wnt11 expression and worse cardiac function in patients with dilated cardiomyopathy or hypertension. The LRP6 (Ser1490) phospho-specific antibody has become an indispensable tool for assessing LRP6 activation, elucidating upstream regulatory kinases, and validating LRP6 activator efficacy. Future research focuses on dissecting LRP6’s activation network and developing specific agonists to target pressure overload-induced heart failure.

3. Research Significance

LRP6 (Ser1490) research holds profound significance for cardiovascular medicine. Pressure overload-induced cardiac fibrosis is a major driver of heart failure, and current treatments have limited efficacy in reversing this process. Elucidating LRP6’s role in regulating paracrine signaling provides a novel endogenous anti-fibrotic pathway, offering new therapeutic targets for diseases like hypertensive heart disease and valvular heart disease.

The discovery that LRP6 (Ser1490) mediates Wnt5a/Wnt11 degradation bridges basic signaling biology and clinical cardiology, explaining how cardiomyocytes modulate the cardiac microenvironment to counteract fibrosis. This research not only deepens our understanding of cardiac remodeling mechanisms but also paves the way for developing LRP6-targeted therapies to preserve cardiac function and improve patient outcomes. Additionally, LRP6 (Ser1490) phosphorylation serves as a potential biomarker for cardiac remodeling progression and therapeutic response.

4. Related Mechanisms, Research Methods, and Product Applications

Mechanisms

LRP6 (Ser1490) suppresses cardiac fibrosis through a paracrine regulation mechanism:

• Pro-fibrotic Signal Secretion: Pressure overload induces cardiomyocytes to secrete Wnt5a and Wnt11, which activate cardiac fibroblasts, promoting their proliferation and transformation into myofibroblasts—driving extracellular matrix deposition.
• LRP6-Mediated Degradation: Activated LRP6 (via Ser1490 phosphorylation) binds CTSD, facilitating the lysosomal uptake and degradation of Wnt5a/Wnt11.
• Fibrosis Suppression: Reduced extracellular Wnt5a/Wnt11 levels block fibroblast activation, inhibiting excessive matrix synthesis and preserving cardiac structure/function.

Research Methods and Product Applications

ANT BIO PTE. LTD.’s high-quality phospho-specific antibody (under the Starter sub-brand) is a cornerstone tool for LRP6 (Ser1490) research, enabling mechanistic studies, drug development, and functional validation:

• Product: Phospho-LRP6 (Ser1490) Recombinant Rabbit mAb (S0B1241)
• Assessing LRP6 Activation: Detects p-Ser1490 levels in cardiomyocytes via Western Blot (WB) or immunofluorescence (IF), correlating receptor activation with cardiac phenotypic improvements in pressure overload models or drug interventions.
• Elucidating Upstream Regulation: Identifies kinases or signaling pathways that modulate LRP6 Ser1490 phosphorylation under pressure overload, uncovering molecular switches for LRP6’s protective effects.
• Validating Activator Efficacy: Serves as a direct pharmacodynamic marker for small-molecule LRP6 activators, confirming target engagement by detecting increased p-LRP6 (Ser1490) levels.
• Clinical and Translational Studies: Analyzes LRP6 activation status in human cardiac tissues, supporting the development of LRP6 as a therapeutic target for heart failure.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with innovative, high-quality reagents and solutions to accelerate scientific discovery and improve human health. We specialize in providing antibodies, recombinant proteins, ELISA kits, and general life science reagents through three dedicated sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Backed by advanced development platforms—including recombinant monoclonal antibody platforms, multi-system recombinant protein expression (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA Platform, and PTM Pan-Modification Antibody Platform—we adhere to stringent international certifications (EU 98/79/EC, ISO9001, ISO13485). Our mission is to be a trusted partner for researchers and clinicians worldwide, delivering reliable products and tailored services that drive breakthroughs in cardiovascular research, therapeutic development, and precision medicine.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.